Carolyn Trott Email

VP - Quality Operations . AlloVir

Current Roles

Employees:
130
Revenue:
$22.6M
About
AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The companyᅢᄁ¬ツᆲ¬トᄁs technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. AlloVirᅢᄁ¬ツᆲ¬トᄁs technology and manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
AlloVir Address
1100 Winter Street
Cambridge, MA
United States

Past Companies

AlloVirVice President - Quality Operations
SanofiHead of Quality - Rare Disease, Oncology, Immunology (Equivalent to VP)
SanofiHead of Site Quality

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.